Home » Stocks » SYN

Synthetic Biologics, Inc. (SYN)

Stock Price: $0.650 USD -0.070 (-9.68%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 85.87M
Revenue (ttm) n/a
Net Income (ttm) -20.59M
Shares Out 90.81M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $0.650
Previous Close $0.720
Change ($) -0.070
Change (%) -9.68%
Day's Open 0.695
Day's Range 0.645 - 0.695
Day's Volume 5,694,338
52-Week Range 0.261 - 1.700

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ROCKVILLE, Md., May 26, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent an...

2 weeks ago - PRNewsWire

ROCKVILLE, Md., May 5, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and...

1 month ago - PRNewsWire

ROCKVILLE, Md., April 28, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent ...

1 month ago - PRNewsWire

ROCKVILLE, Md., April 14, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent ...

1 month ago - PRNewsWire

ROCKVILLE, Md., April 1, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent a...

2 months ago - PRNewsWire

Synthetic Biologics (SYN) stock is soaring higher on heavy trading Tuesday even without a lack of news concerning the company. The post Synthetic Biologics: 6 Things for SYN Stock Investors to Know as t...

5 months ago - InvestorPlace

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Synthetic Biologics, Inc (SYN) CEO Steven Shallcross on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About SYN

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant... [Read more...]

Industry
Biotechnology
IPO Date
Jun 26, 2006
CEO
Steven Shallcross
Employees
10
Stock Exchange
NYSEAMERICAN
Ticker Symbol
SYN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for SYN stock is "Buy." The 12-month stock price forecast is 1.88, which is an increase of 189.10% from the latest price.

Price Target
$1.88
(189.10% upside)
Analyst Consensus: Buy